Amylyx Stock Has The Bull Case Changed After Phase III Trial Success

Simply Wall St · 11/07 14:22
  • Amylyx Pharmaceuticals reported third quarter 2026 net loss of US$45.49 million and nine month loss of US$130.2 million, while preparing an NDA submission for avexitide after positive phase III LUCIDITY results in post bariatric hypoglycemia.
  • The business paired deeper reported losses with a US$545 million equity raise and early commercial build out for a potential first in class PBH therapy. This concentrates operational risk and opportunity around avexitide execution.
  • We will now examine how Amylyx Pharmaceuticals’ investment narrative could shift as avexitide’s positive Phase III data moves toward an FDA filing.

Scan beyond Amylyx Pharmaceuticals and size up other drug developers preparing for potential breakout catalysts in our hand picked 35 healthcare AI stocks.

Amylyx Pharmaceuticals Investment Narrative Recap

For Amylyx Pharmaceuticals, the central belief is that avexitide can move from a single late stage asset to a real commercial product in post bariatric hypoglycemia. The business is still pre revenue and reported a third quarter 2026 net loss of US$45.49 million and a nine month loss of US$130.2 million, so the operating story is about disciplined cash use and execution rather than current earnings.

The most important near term catalyst is clear FDA progress for avexitide after the positive Phase III LUCIDITY data and the planned NDA filing. The biggest risk is concentration. A larger loss profile, expanding commercial build, and reliance on GLP 1 antagonist programs mean that any regulatory delay or post launch uptake challenges could keep losses elevated for longer.

The recent third quarter report is the key announcement to focus on alongside the LUCIDITY readout. Management reported a quarterly loss of US$45.49 million, compared with US$34.39 million a year earlier, and a nine month loss of US$130.2 million, compared with US$111.74 million a year ago. Basic and diluted loss per share from continuing operations for the quarter were US$0.38, roughly in line with US$0.37 a year ago.

This update matters because it shows the cost base that supports the avexitide push, including launch readiness work and broader pipeline spend. With roughly US$545 million raised in equity and no meaningful revenue, the story now leans on how efficiently Amylyx Pharmaceuticals converts that spending into regulatory milestones, payer access groundwork, and eventual commercial readiness for PBH and follow on GLP 1 antagonist programs.

Amylyx Pharmaceuticals’ current analyst narrative projects forecast revenue of US$343.4 million and earnings of US$86.8 million by 2029, which would mean a move from today’s reported loss of US$152.1 million to positive earnings and an earnings swing of about US$238.9 million over that period.

Uncover how Amylyx Pharmaceuticals' fair value indicates a 44% potential upside to its current price, which could close faster than many investors expect.

NasdaqGS:AMLX 1-Year Stock Price Chart
NasdaqGS:AMLX 1-Year Stock Price Chart

Exploring Other Perspectives

One alternative Amylyx Pharmaceuticals story places far more emphasis on commercial uptake risk rather than solely on trial success. The most cautious analysts were only penciling in US$84.9 million of revenue and US$14.4 million of earnings by 2029. This represents a much leaner path than consensus and illustrates how sharply views can differ before this latest LUCIDITY and earnings news is fully absorbed.

Explore another Amylyx Pharmaceuticals fair value estimate, including one that suggests it could be worth just $42.36!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider doing your own independent research and go with your instincts.

Looking for more investment ideas beyond Amylyx Pharmaceuticals?

Once you have a view on Amylyx Pharmaceuticals, it can help to widen the lens and compare it with other listed businesses that fit different risk and return profiles. The Simply Wall St Screener lets you do that quickly by filtering for qualities that matter to you, whether that is balance sheet strength, income potential, or under the radar quality.